OBJECTIVE： To study the effect of Shenkang injection on the irbesartan pharmacokinetics in rats in vivo. METHODS： 18 SD rats were randomly divided into control group （normal saline） and Shenkang injection （calculated by crude drug as 4 g/kg）， 9 in each group， which were intraperitoneally injected twice a day， for 7 d. After 1 h of last administration， 25 mg/kg irbesartan was intragastrically administrated. 0.3 mL sample blood was taken in fundus venous plexus before administration of irbesartan and after 0.25， 0.5， 1， 2， 4， 8， 12， 24， 32， 48， 56， 72， 96 h of administration. Using biphenyl diester as inner standard， HPLC was adopted to determine the plasma concentration of irbesartan in plasma of rats， and pharmacokinetic parameters were calculated by using non-compartmental model in Phoenix WinNolin® 6.1 pharmacokinetic software. RESULTS： After intragastrically administrated irbesartan in rats in control group and Shenkang injection group， AUC0-96 h were （28.82±10.49）， （35.64±9.99） mg·h/L； cmax were （0.64±0.15）， （0.76±0.33） mg/L； tmax were （13.07±16.70）， （10.23±3.97） h； CLZ/F were （0.85±0.35）， （0.63±0.21） L/（h·kg）； VZ/F were （38.24±24.87）， （30.99±9.75） mL/kg respectively， with no statistical significances （P＞0.05）. CONCLUSIONS： Shenkang injection will not affect the in vivo pharmacokinetics process of irbesartan in normal dose on rats.